Wockhardt Shares Jump 6% on USFDA NDA Acceptance for Zaynich
Wockhardt's share price surged over 6% after the USFDA accepted its New Drug Application for Zaynich, a novel antibiotic. Discover the details and market impact.
Category : Search result: Zaynich
Wockhardt's Zaynich NDA Accepted by USFDA, Shares Soar 19%
Mumbai's Wockhardt creates history as USFDA accepts its New Drug Application for antibiotic Zaynich, a first for an Indian firm. Shares surge 19%. Read more.
Wockhardt Stock Jumps on US FDA Nod for Novel Antibiotic
Wockhardt shares surged 19.3% after US FDA accepted its New Drug Application for Zaynich, a first-in-class antibiotic. This marks a historic first for an Indian pharma company's New Chemical Entity.
India develops indigenous antibiotic for respiratory infections
Indian scientists develop groundbreaking antibiotic Zaynich to combat drug-resistant respiratory infections, marking a major achievement in India's healthcare innovation journey.
Page 1 of 1